Peng Chunyan, Shen Shanshan, Zhang Xiaoqi, Zou Xiaoping
Department of Gastroenterology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, China.
Rare Tumors. 2013 May 2;5(1):e6. doi: 10.4081/rt.2013.e6. Print 2013 Feb 11.
Small cell carcinoma of the gastrointestinal tract is a rare and aggressive neuroendocrine tumor. This study aims to analyze the clinical characteristics and potential prognostic factors for patients with limited stage small cell carcinoma of the gastrointestinal tract. The records of 27 patients with limited stage small cell carcinoma of the gastrointestinal tract, who all received surgery with lymphadenectomy, were retrieved and analyzed retrospectively. The median age of patients was 60 years old (range 38-79). The primary locations of tumor were the esophagus (74.1%) and stomach (14.8%). The rate of preoperative accurate diagnosis (16.7%) was low for small cell carcinoma of the esophagus and stomach. 40.7% of all the patients had regional lymph node metastases. Five patients underwent surgery alone, and the other 22 were treated with surgery + postoperative chemotherapy. All patients had disease progression or recurrence. The overall median survival time was 10 months and the 1-year survival rate was 37.0%. Patients who received postoperative chemotherapy had a median survival time of 12 months, which was superior to the 5-month survival of for those who only had surgery (P<0.0001). TNM stage (P=0.02) and postoperative chemotherapy (P<0.0001) were considered as two prognostic factors in uni-variate analysis. Postoperative chemotherapy was a significant independent prognostic factor in multivariate analysis (P=0.01). The prognosis for patients with limited stage small cell carcinoma of the gastrointestinal tract remains dismal, however, postoperative chemotherapy may have the potential to improve the outcome for these patients.
胃肠道小细胞癌是一种罕见且侵袭性强的神经内分泌肿瘤。本研究旨在分析局限性胃肠道小细胞癌患者的临床特征及潜在预后因素。回顾性检索并分析了27例局限性胃肠道小细胞癌患者的病历,这些患者均接受了手术及淋巴结清扫术。患者的中位年龄为60岁(范围38 - 79岁)。肿瘤的主要部位是食管(74.1%)和胃(14.8%)。食管和胃小细胞癌的术前准确诊断率较低(16.7%)。所有患者中有40.7%发生区域淋巴结转移。5例患者仅接受了手术,另外22例接受了手术 + 术后化疗。所有患者均出现疾病进展或复发。总体中位生存时间为10个月,1年生存率为37.0%。接受术后化疗的患者中位生存时间为12个月,优于仅接受手术患者的5个月生存期(P<0.0001)。单因素分析中,TNM分期(P = 0.02)和术后化疗(P<0.0001)被视为两个预后因素。多因素分析中,术后化疗是一个显著的独立预后因素(P = 0.01)。局限性胃肠道小细胞癌患者的预后仍然很差,然而,术后化疗可能有改善这些患者预后的潜力。